{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:40:12Z","timestamp":1791945612336,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jtocrr.2021.100231","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T11:47:54Z","timestamp":1631879274000},"page":"100231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene"],"prefix":"10.1016","volume":"2","author":[{"given":"Azam","family":"Ghafoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idrees","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Mallory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Garcia","family":"Agra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun S.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjistha","family":"Sengupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffit","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2021.100231_bib1","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2021.100231_bib2","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2021.100231_bib4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2021.100231_bib5","first-page":"566","article-title":"The mortality of amphibole miners in South Africa, 1946\u201380","volume":"49","author":"Sluis-Cremer","year":"1992","journal-title":"Br J Ind Med"},{"key":"10.1016\/j.jtocrr.2021.100231_bib6","doi-asserted-by":"crossref","first-page":"13618","DOI":"10.1073\/pnas.1105887108","article-title":"Erionite exposure in North Dakota and Turkish villages with mesothelioma","volume":"108","author":"Carbone","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtocrr.2021.100231_bib7","first-page":"971","article-title":"Therapeutic radiation for lymphoma and risk of second primary malignant mesothelioma","volume":"28","author":"Chang","year":"2017","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.jtocrr.2021.100231_bib8","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/cam4.656","article-title":"Radiation-induced mesothelioma among long-term solid cancer survivors: a longitudinal analysis of SEER database","volume":"5","author":"Farioli","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtocrr.2021.100231_bib9","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(00)04013-7","article-title":"Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey","volume":"357","author":"Roushdy-Hammady","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2021.100231_bib10","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1158\/0008-5472.CAN-05-4642","article-title":"Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey","volume":"66","author":"Dogan","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtocrr.2021.100231_bib11","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtocrr.2021.100231_bib12","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtocrr.2021.100231_bib13","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/jnci\/djy171","article-title":"Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide","volume":"110","author":"Walpole","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jtocrr.2021.100231_bib14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc3459","article-title":"BAP1 and cancer","volume":"13","author":"Carbone","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtocrr.2021.100231_bib15","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1073\/pnas.1821510116","article-title":"Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy","volume":"116","author":"Hassan","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtocrr.2021.100231_bib16","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/sj.onc.1201861","article-title":"BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 ring finger and enhances BRCA1-mediated cell growth suppression","volume":"16","author":"Jensen","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.jtocrr.2021.100231_bib17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1158\/0008-5472.CAN-08-3355","article-title":"BRCA1-associated protein 1 interferes with BRCA1\/BARD1 RING heterodimer activity","volume":"69","author":"Nishikawa","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtocrr.2021.100231_bib18","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.jtocrr.2021.100231_bib19","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2021.100231_bib20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2021.100231_bib21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2021.100231_bib22","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2021.100231_bib23","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2021.100231_bib24","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/annonc\/mdw133","article-title":"Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1\/2 mutation: a multistudy analysis of response rates and safety","volume":"27","author":"Matulonis","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2021.100231_bib25","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2021.100231_bib26","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2021.100231_bib27","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.17140\/POJ-3-e011","article-title":"PARP inhibitors in pancreatic cancer: from phase I to plenary session","volume":"3","author":"Patel","year":"2019","journal-title":"Pancreas (Fairfax)"},{"key":"10.1016\/j.jtocrr.2021.100231_bib28","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/annonc\/mdw048","article-title":"PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations","volume":"27","author":"Helleday","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2021.100231_bib29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtocrr.2021.100231_bib30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2021.100231_bib31","doi-asserted-by":"crossref","first-page":"100007","DOI":"10.1016\/j.xcrm.2020.100007","article-title":"Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer","volume":"1","author":"Roper","year":"2020","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jtocrr.2021.100231_bib32","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows\u2013Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jtocrr.2021.100231_bib33","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.jtocrr.2021.100231_bib34","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.molonc.2016.07.003","article-title":"Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy","volume":"10","author":"Bauss","year":"2016","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jtocrr.2021.100231_bib35","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.molcel.2020.04.035","article-title":"Biomarker-guided development of DNA repair inhibitors","volume":"78","author":"Cleary","year":"2020","journal-title":"Mol Cell"},{"key":"10.1016\/j.jtocrr.2021.100231_bib36","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jtho.2020.01.012","article-title":"Sensitivity of mesothelioma cells to PARP inhibitors is not dependent on BAP1 but is enhanced by temozolomide in cells with high-schlafen 11 and low-O6-methylguanine-DNA methyltransferase expression","volume":"15","author":"Rathkey","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2021.100231_bib37","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1016\/j.jtho.2020.02.028","article-title":"The Association of BAP1 loss-of-function with the defect in homologous recombination repair and sensitivity to PARP-targeted therapy","volume":"15","author":"Yang","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2021.100231_bib38","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00280-017-3401-y","article-title":"Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition","volume":"80","author":"Srinivasan","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jtocrr.2021.100231_bib39","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jtho.2017.03.023","article-title":"A\u00a0novel BRCA1-associated protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair","volume":"12","author":"Parrotta","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2021.100231_bib40","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12885-019-5314-0","article-title":"Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in\u00a0vitro","volume":"19","author":"Borchert","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtocrr.2021.100231_bib41","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(20)30390-8","article-title":"Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial","volume":"9","author":"Fennell","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"suppl 15","key":"10.1016\/j.jtocrr.2021.100231_bib42","article-title":"Phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response (DDR) pathway deficient neoplasms (NCT03207347)","volume":"38","author":"Ali","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2021.100231_bib43","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/j.cllc.2020.07.014","volume":"22","author":"Passiglia","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtocrr.2021.100231_bib44","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1139\/O07-069","article-title":"Mre11-Rad50-Nbs1 is a keystone complex connecting DNA repair machinery, double-strand break signaling, and the chromatin template","volume":"85","author":"Williams","year":"2007","journal-title":"Biochem Cell Biol"},{"key":"10.1016\/j.jtocrr.2021.100231_bib45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrm3047","article-title":"The MRE11 complex: starting from the ends","volume":"12","author":"Stracker","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jtocrr.2021.100231_bib46","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/emboj.2009.206","article-title":"PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination","volume":"28","author":"Bryant","year":"2009","journal-title":"EMBO J"},{"key":"10.1016\/j.jtocrr.2021.100231_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100041","article-title":"Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in\u00a0vitro","volume":"9","author":"Koppensteiner","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jtocrr.2021.100231_bib48","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.canlet.2013.10.034","article-title":"Poly (ADP-ribose) polymerase inhibitor LT-626: sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells","volume":"343","author":"McPherson","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jtocrr.2021.100231_bib49","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3324\/haematol.2012.079251","article-title":"Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies","volume":"98","author":"Gaymes","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.jtocrr.2021.100231_bib50","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10549-012-2188-0","article-title":"Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib","volume":"135","author":"Daemen","year":"2012","journal-title":"Breast Cancer Res Treat"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364321000904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364321000904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:36:29Z","timestamp":1762986989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364321000904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S2666364321000904"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100231","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100231","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100231"}}